Sorrento shrugs off an anonymous private equity group’s $1B offer to buy the company
San Diego-based Sorrento Therapeutics isn’t going the M&A route — at least not today.
The biotech caused quite a stir when it put out word …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
